Holen Sie sich die Stockscreener-App
8.21
1.48%
0.12
Vorhandelsmarkt:
8.21
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com
Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance
Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com
FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India
Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener
Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan
Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com
Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World
Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha
Amneal recalls oral antibiotic due to bacterial contamination - MSN
AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus
Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com
Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK
Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey
Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus
Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus
Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News
Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire
Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan
Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Pharyngitis Treatment Market with Antibiotics and Home - openPR.com
3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance
Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com
Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World
1.05%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):